You are here

  • Home
  • Archive
  • Volume 27, Issue 3
  • When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

Article info

Article menu
Download PDFPDF
EBM opinion and debate
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

Authors

  • Myung S Kim Department of Medicine, Division of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA PubMed articlesGoogle scholar articles
  • Vinay Prasad Department of Medicine, University of California San Francisco, San Francisco, California, USA Department of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Vinay Prasad, Department of Medicine, University of California San Francisco, San Francisco CA 94158, USA; vinayak.prasad{at}ucsf.edu
View Full Text

Citation

Kim MS, Prasad V
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100
BMJ Evidence-Based Medicine 2022;27:151-152.

Publication history

  • Accepted May 9, 2021
  • First published June 3, 2021.
Online issue publication 
May 24, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.